1Graduate School of Integrated Science, Yokohama City University, 1-7-29 Suehirocho, Tsurumi, Yokohama, Kanagawa 230-0045, 2Graduate School of Science and Engineering and 4Division of Plant Molecular Biotechnology, Cell-Free Science and Technology Research Center, Ehime University, 3 Bunkyocho, Matsuyama, Ehime 790-8577 and 3Graduate School of Biological Sciences, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0101, Japan
5 To whom correspondence should be addressed. E-mail: hiroakih{at}tsurumi.yokohama-cu.ac.jp
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Keywords: Escherichia coli expression system/isotopic labeling/NMR/TA cloning/thioredoxin fusion protein
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
When multidomain proteins are subjected to partial proteolysis, polypeptide fragments may be liberated which retain the full biological activity of the parent domains. The ability of peptides to retain biological activity has been used to develop therapeutic agents against disease (Lauta, 2000; Jacobsen, 2002
; Nathisuwan and Talbert, 2002
), peptide vaccines (Celis, 2002
) and diagnostic imaging reagents (Behr et al., 2001
). Currently the most common method of peptide production is solid-state synthesis. However, this technique is hampered by both high cost and relatively low yields, especially for larger peptides (e.g. >50 residues). Furthermore, solid-state synthesis of isotopically labeled peptides for multidimensional NMR studies is not a viable option, owing to the prohibitively high cost.
Incorporation of isotopic labels (13C, 15N, 2H) within a polypeptide using a bacterial recombinant system is an alternative to the chemical synthetic approach. Expression can potentially yield high levels of peptide at relatively low cost, with easy incorporation of isotopic labels. Unfortunately, expression of peptides in vivo has not been the preferred option for high-throughput studies because plasmid construction is time consuming. In addition, the unstructured state of peptides in the bacterial cytosol makes them susceptible to proteases and may also cause solubility problems. One solution to high-yield recombinant peptide production is the use of a fusion protein construct, which can aid peptide stability and solubility following expression. Fusion proteins incorporating various affinity tags and proteolytic cleavage sites can assist in the purification and subsequent peptide fragment production. Several groups have reported successfully using fusion constructs encoding a hydrophobic protein, which produces an insoluble product that is sequestered within inclusion bodies (Jones et al., 2000; Majerle et al., 2000
; Sharon et al., 2002
). However, reconstitution of inclusion body proteins involves an additional step using chemical denaturants for subsequent peptide production. A cytosolic soluble protein as a fusion partner, such as glutathione S-transferase (Smith and Johnson, 1988
; Kami et al., 2002
) and GB-1 (Lindhout et al., 2003
) can also be used. However, recovery of full-length peptide from potentially contaminated shorter fragments caused by endogenous proteolysis must be achieved by other methods, such as affinity purification using a C-terminal Hisx6 tag (Lindhout et al., 2003
). Alternatively, periplasmic thioredoxin (TRX) as the fusion partner was proposed by several groups. (LaVallie et al., 1993
; Uegaki et al., 1996
) The advantage of the TRX fusion approach over other techniques is the production of a soluble fusion protein in the bacterial periplasmic space via the non-standard secretion pathway, resulting in high expression levels together with significant protection against endogenous proteases.
In this paper, we report a high-throughput TRX fusion protein expression system combined with the novel PRESAT-vector (Potential Restriction Enzyme Selectable Asymmetric T-vector)-based TA cloning methodology (Goda et al., 2004). We have recently developed the PRESAT-vector methodology, which is a technique of unidirectional TA cloning at the multiple cloning site to generate GST-fusion protein expression vectors. Thus, DNA encoding the peptide of interest with a 3'-dA overhang can be incorporated into the vector using the one-step TA cloning protocol. We constructed plasmids encoding seven different peptides fused to TRX, a 114-amino acid soluble globular domain. Expression was under the control of a strong T7 promoter and the recombinant Hisx6-tagged proteins were then purified by metal affinity chromatography. The ability of the TRX fusion system to express many different peptide fragments is demonstrated in this study. We have cloned, expressed and purified seven different peptides, PACAP27, VIP, VIP(628) and VIP(1128), Hrs-UIM, STAM2-UIM and MJD1-UIM. In addition, we used three different methods for preparation of DNA coding the peptide of interest, polymerase chain reaction (PCR) amplified cDNA, as well as synthetic DNA and semi-synthetic DNA. The use of semi-synthetic DNA, in which partly overlapped oligonucleotides were synthesized and subjected to enzymatic extension, is beneficial to reduce the cost and the risk of long synthetic oligonucleotides. An additional three bases (5'-ACC) were included in the reverse strand, which allowed subsequent restriction enzyme selection for ORF orientation after TA-vector cloning. The methodology is quick and highly efficient. Moreover, we demonstrate the ability of this system to produce isotopic labeling of peptides for NMR studies and to provide a strong prospect for future production of peptides for various industrial, pharmaceutical and general research applications.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Restriction enzymes NheI, NdeI, XhoI and AhdI were obtained from New England Biolabs and KpnI from Toyobo. T4 DNA ligase, T4 DNA polymerase, Wizard plasmid miniprep kit and Wizard SV DNA gel purification kit were purchased from Promega. Taq DNA polymerase was purchased from either Invitrogen or Takara. The cloning vector pGEM-T was purchased from Promega and the expression vectors pET21b and pET32a from Novagen. All oligonucleotide sequences are summarized in Table I. Oligonucleotide primers were obtained from Hokkaido System Science (Sapporo, Japan). Factor Xa was purchased from New England Biolabs.
|
We chose a pET-based vector as template to design the TRX fusion constructs because of the generally recognized high level of expression afforded by the T7 promoter (Studier and Moffatt, 1986; Miroux and Walker, 1996
). Our prototype PACAP27G expressing vector, pET32aPACAP27G, was constructed from pET32a into which a synthetic 129 bp DNA fragment encoding PACAP27G was inserted (see Supplementary Figure S1, available at PEDS online). The linker sequence of our prototype vector contained an enterokinase cleavage site, which caused non-specific cleavage on removal of TRX-tag from PACAP27G (data not shown). In this study, we incorporated a new minimum linker sequence containing a hexa-histidine (Hisx6) tag and Factor Xa cleavage site C-terminal to TRX. For this purpose, the linker sequence containing Hisx6 and the Factor Xa cleavage site were attached N-terminal to the PACAP27G gene by PCR using the primers dGCTAGCCATCACCACCACCACCACAGCAGCGGCATTGACGGCCGGCATAGCGATGGCATCTTTACC and dCTCGAGGAATTCACTAGTGGATCCAAGCTTTTATTAGCCCAGCAC and then subcloned into pGEM-T. An NdeI fragment containing the thioredoxin gene from pET32a and an NheIXhoI fragment containing Hisx6 plus Factor Xa plus PACAP27G was incorporated into the NdeI site and the NheI and XhoI sites of pET21b, respectively.
Preparation of pET-TRX-PRESAT vector
pET-TRX-PACAP27GC was converted to pET-TRX-PRESAT according to the PRESAT-vector methodology (Goda et al., 2004). For this purpose, two AhdI sites were created after the Factor Xa multiple cloning site, while one endogenous AhdI site within the AmpR genetic marker was disrupted using a combination of PCR mutation and site-directed mutagenesis. Firstly an
150 bp fragment was PCR amplified using primers dGCACTAGTGGTTCTGGTTCTGGCGCTAGCCATCACCACCAC and dTTGTTAGCAGCCGGATCTCA and pET-TRX-PACAP27GC as a template. This fragment was subcloned into pGEM-T vector (Promega) according to the standard T/A-cloning protocol for further mutation. This pGEM-T subcloned linker contains the region between the NheI and XhoI sites illustrated in Figure 1a, followed by a GSGSG pentapeptide extension, which will be used for further optimization of the linker length between thioredoxin and Hisx6 tag (data not shown). Then, starting from this pGEM-T subcloned linker, the first AhdI site was engineered by PCR mutation using primers dGGATCCGACCATTGGTCTTATTAGCCCAGCACCGCCG and dGATTTAGGTGACACTATAG. This PCR fragment was digested by NheI and BamHI and then ligated between NheI and BamHI sites of the pET-TRX-PACAP27GC replacing the region containing the TRX_PACAP27G gene. Finally, creation and disruption of remaining AhdI sites was performed simultaneously using 5'-phosphorylated mutation primers, d-pGTTATCTACACCACGGGGAGCCAGGCAACTATGG and d-pGGCATTGACGGTCGGTCTAGCGATGGCATC, and the Gene Editor mutagenesis kit (Promega).
|
The DNA fragments encoding PACAP27G and Hrs-UIM were amplified by PCR using Taq DNA polymerase and plasmids harboring the PACAP27G and mouse Hrs gene as template. Similarly, DNA fragment encoding STAM2-UIM was amplified by PCR from QuickClone(TM) mouse liver first strand cDNA pool (Clonetech). The synthetic DNA fragments encoding VIP(1128)G were synthesized using optimized codons for Escherichia coli, as indicated in Table I. The semi-synthetic DNA fragments for VIP-G, VIP(628)G and MJD1-UIM were synthesized as indicated in Table I. Each pair of forward and reverse primers (10 pmol) were mixed, annealed and subjected to enzymatic extension by T4 DNA polymerase at 37°C for 1 h. The DNA was then ethanol precipitated and incubated with Taq polymerase (5 U) and 1 mM dATP at 70°C for 1 h. For each gene we introduced double stop codons and an extra 5'ACC base at the terminus of the antisense DNA strand. In addition, an extra 5'-AGA sequence at the terminus of each sense strand was attached, corresponding to the fourth Arg residue of the Factor Xa cleavage site. Note that the PCR product amplified with Taq DNA polymerase contains a 3'-single overhanging dA base at both termini. Thus the synthetic oligonucleotides for VIP(1128)G must contain an additional 3'-dA base on each strand. The sense and antisense oligonucleotides were denatured together at 95°C for 5 min and then annealed by slow cooling for 1 h prior to the ligation reaction.
Single-step cloning and ORF selection of peptide genes into pET-TRX-PRESAT vectors
The parent pET-TRX-PRESAT vector was digested with AhdI, agarose gel purified and ligated to individual DNA fragments. Following transformation into E.coli DH5, plasmid DNA was purified and subjected to KpnI restriction digestion to select for ORF orientation. Approximately 0.1 µg of the plasmid was treated with KpnI (10 units, 1 h, 37°C). Finally, corresponding vectors were transformed into E.coli BL21(DE3) for subsequent expression. Five randomly selected colonies containing each respective TRX fusion vector were picked and grown in 3 ml LB (plus 50 µg/ml ampicillin) to an OD600 of 0.4 at 30°C and then induced with 1 mM isopropyl D-thiogalactopyranoside (IPTG) for 3 h. The efficiency of ORF selection and solubility of the expressed protein was assessed by disrupting the cells in a sonicator (BioRuptor, Showa Electric, Japan) and analyzing the clarified cell-free extract by SDSPAGE (15% gel).
Labeling of TRX_VIP-G and TRX_MJD1-UIM fusion proteins
For 15N labeling of the fusion proteins TRX_VIP-G and TRX_MJD1-UIM, M9 medium containing 0.5 g/l [15N]NH4Cl as the sole nitrogen source, 0.1% (w/v) glycerol and 4 g/l of glucose was used. E.coli harboring either pET-TRX_VIP-G or pET-TRX_MJD1-UIM was grown in 100 ml of 15N-enriched M9 medium containing 50 µg/ml ampicillin for 16 h. The cells were divided in two and then each 50 ml were transferred into 0.45 l cultures of the same medium in two 1 l baffled flasks. IPTG induction was carried out as described earlier except that the cells were incubated for 6 h prior to harvesting.
Purification of TRX_VIP-G and TRX_MJD1-UIM fusion proteins
BL21(DE3) cells from 0.5 l of M9 medium that expressed TRX_VIP-G were pelleted, resuspended in 12 ml of 20 mM TrisHCl (pH 8.0), 20% (w/v) sucrose, 2.5 mM EDTA and incubated for 20 min on ice. The cells were gently collected and osmotically disrupted by resuspending into 12 ml of lysis buffer containing 20 mM TrisHCl (pH 8.0). This step was repeated twice and all supernatants were pooled.
For TRX_MJD1-UIM, BL21(DE3) cells from 0.5 l of M9 medium were pelleted, resuspended in 10 ml of 50 mM potassium phosphate buffer (pH 7.8), 0.4 M KCl and disrupted by sonication. Cell debris was removed by centrifugation (50 000 g for 20 min at 4°C), followed by passing the extracts through a 1 ml column of fast-flow DEAE-Sepharose (Amersham Pharmacia Biotech).
The cleared extracts either from osmotic disruption or sonication were loaded on to a 5 ml column of fast-flow chelating Sepharose, previously charged with 50 mM NiSO4 and equilibrated in 20 mM imidazole and 50 mM TrisHCl (pH 7.6). The column was then washed with 50 mM imidazole and 50 mM TrisHCl (pH 7.6), followed by fusion protein elution with 0.1 M (TRX_MJD1-UIM) or 0.2 M (TRX_VIP-G) of imidazole and 50 mM TrisHCl (pH 7.6). Fusion proteins eluted from the column (2 ml) were dialyzed against 1 l of buffer containing 0.1 M NaCl, 50 mM TrisHCl (pH 8.0) at 4°C for 16 h.
Factor Xa cleavage of VIP-G and MJD1-UIM from TRX fusion proteins and purification of peptides
The solution of TRX_VIP-G and TRX_MJD1-UIM fusion proteins at a protein concentration of 5 mg/ml were adjusted to a condition for Factor Xa cleavage reaction, containing 0.1 M NaCl, 2 mM CaCl2 and 50 mM TrisHCl (pH 8.0), by adding an aliquot of 0.2 M CaCl2. Approximately 2.5 mg of fusion proteins were digested. Factor Xa (10 units) was added to a final molar ratio of 10 units/mg substrate. Digestion was carried out at room temperature for VIP-G and at 4°C for MJD1-UIM for 2 h. Proteolysis was terminated by adding 2.3 volumes of cold (30°C) acetone to precipitate the protein tags, which were then removed by centrifugation. Solutions were then fully dried to remove all organic solvent. Samples were analyzed on a reversed-phase C18 HPLC column with a linear gradient of acetonitrile and a major peak was collected and verified in terms of MWs by MALDI-TOF mass spectrometry. A peak containing pure peptide were pooled and lyophilized to dryness to remove all organic solvent.
Expression and purification of other peptides
The VIP-related peptides VIP(628)G and VIP(1128)G were expressed, cleaved by Factor Xa and purified according to the same protocol as for VIP-G described above. PACAP27G and the UIM-related peptides, Hrs-UIM and STAM2-UIM, were expressed, Factor Xa treated and purified according to the same protocol as for MJD1-UIM. The typical yields of the peptides studied are summarized in Table II.
|
NMR experiments were performed on a Bruker AvanceDRX 500 MHz NMR spectrometer equipped with a cryogenic triple resonance probe and Z-axis pulsed-field gradients. All recorded spectra were referenced to an external sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) standard. Approximately 80 µg of [15N]VIP-G was dissolved in 0.25 ml of H2OD2O (9:1) containing 50 mM potassium phosphate buffer at pH 7.2, with and without 1% w/v dodecylphosphocholine (DPC) micelle. Approximately 70 µg of [15N]MJD1-UIM was dissolved in 0.3 ml of H2OD2O (9:1) containing 5 mM KCl, 1 mM EDTA and 20 mM potassium phosphate buffer at pH 6.8, in the absence and presence of 2 and 4 mol equiv. of human Ub. HSQC spectra (Neri et al., 1989) modified with a gradient sensitivity enhancement (Kay et al., 1992
) were acquired with eight transients and 256 increments at 298 K and zero filled during spectral processing. All two-dimensional spectra were processed with nmrPipe (Delaglio et al., 1995
) and analyzed with the program nmrDraw (Delaglio et al., 1995
).
![]() |
Results and discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Three different strategies for the preparation of DNA encoding the peptide of interest were demonstrated. For peptides shorter than 25 residues, chemically synthesized oligonucleotides up to 75 bases for both forward and reverse strands were synthesized. In this study, DNA encoding VIP(1128)G was synthesized. DNA encoding peptides between 20 and 35 residues in length were generated by an enzymatic semi-synthesis method instead of fully synthesized oligonucleotides, owing to the high cost involved. In this case, only the 5' portion of the DNA sequence of each strand was synthesized with at least 15 bases of cohesive ends. The reaction conditions for enzymatic semi-synthesis were carefully adapted to the PRESAT-vector system. The sense and antisense strands were mixed, allowed to anneal, extended by T4 DNA polymerase and finally a single dA extension was added by Taq DNA polymerase for subsequent TA cloning. The DNA fragments corresponding to VIP-G, VIP(628)G and MJD1-UIM were prepared by this method. Alternatively, DNA encoding peptides >30 residues in length or peptides for which the genes were already cloned were amplified by a standard PCR protocol. In this study DNA encoding PACAP27G, Hrs-UIM and STAM2-UIM were amplified by PCR.
Figure 1 shows schematic illustrations of the pET-TRX vectors used in this study with the sequence of the multiple cloning sites. Originally, an expression vector of TRX_PACAP27G fusion protein was constructed according to a conventional genetic method, yielding pET-TRX-PACAP27GC (Figure 1a), where the superscript C represents a conventional construction method. The multiple cloning site of pET-TRX-PACAP27GC was modified with a pair of AhdI restriction sites, one within the Factor Xa cleavage site and a second downstream of the stop codon of PACAP27G. This vector was linearized with AhdI, yielding an asymmetric T-vector named pET-TRX-PRESAT, as shown in Figure 1b. PCR-amplified fragments and synthetic and semi-synthetic DNA fragments were then cloned according to the PRESAT-vector cloning methodology (Goda et al., 2004). When PCR-amplified DNA fragments encoding PACAP27G were cloned into pET-TRX-PRESAT, yielding pET-TRX-PACAP27GP, the coding amino acid sequence of TRX_PACAP27G fusion protein is exactly the same as that expressed by pET-TRX-PACAP27GC, where the superscript P represents a PRESAT-vector.
Figure 2 shows the concept of one-step construction of TRX-fusion vector using pET-TRX-PRESAT according to PRESAT-vector methodology (Goda et al., 2004). In brief, DNA fragments with a 3' single dA overhang were ligated with pET-TRX-PRESAT vector linearized by AhdI restriction enzyme. Ligated vector was transformed into E.coli for amplification and a plasmid DNA preparation was then treated with KpnI. Since one of the asymmetric TA cloning sites was designed as a partial KpnI recognition sequence, only the ligated plasmid with insert of the undesired (reverse) orientation contains a newly formed KpnI site. Consequently, the undesired product is readily eliminated for the subsequent transformation into E.coli BL21(DE3) host for high-level protein expression (Miroux et al., 1996
).
|
|
|
For simplicity, we chose to show an example of the purification of TRX_VIP-G (Figure 4b). A band of the predicted size can be seen in the induced extract indicating a relatively high level of expression. Typically the yield of protein was 50 mg/l from expression in LBG. The efficiency of Factor Xa treatment and acetone extraction of VIP-G from the TRX-tag was also demonstrated by SDSPAGE (Figure 4b, lanes 5 and 6). The TRX tag was efficiently removed from the peptide by solvent precipitation using acetone prior to reversed-phase HPLC purification. This simple procedure increases the capacity of the peptide to be loaded on to an HPLC column with acceptable resolution. Finally, MALDI-TOF mass spectrometry of the purified peptides confirmed that cleavage was taking place specifically at the targeted Factor Xa site (Figure 4c).
The efficiency of 15N labeling of VIP-G was examined by 1H15N HSQC spectra with or without 1% (w/v) DPC micelles (Figure 5). VIP-G is predominantly unstructured in solution, as evidenced by the limited chemical shift dispersion in the spectra (7.88.6 p.p.m. in 1H) and the limited number of HSQC peaks (21 clearly detected peaks out of 28 expected), as shown in Figure 5a. The number of observed peaks increased with the addition of DPC micelle and 27 amide protons were detected, with drastic chemical shift changes of some peaks, in addition to large chemical shift dispersion (7.18.7 p.p.m. in 1H, Figure 5b). The result suggests that VIP-G adopts an -helical conformation on binding to DPC micelle, which mimics the environment of cellular phospholipid membranes. Induction of an
-helical conformation of PACAP27 upon membrane binding as a prerequisite step for receptor binding of PACAP27 was observed by NMR and a two-step ligand transportation model to the integral seven-transmembrane receptors has been proposed (Inooka et al., 2001
). In addition, preincubation of VIP with phospholipid may potentiate physiological activity of VIP, such as vasodilation, through induction of an
-helical conformation (Rubinstein et al., 2001
). The importance of a membrane-associated pathway on binding of a peptide hormone to its receptor was also exemplified by cholecystokinin-8 (Giragossian et al., 2002
). Structural studies of VIP and VIP-related vasoactive peptides using isotopically labeled peptides would be of enormous interest.
|
|
![]() |
Acknowledgments |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Behr,T.M., Gotthardt,M., Barth,A. and Behe,M. (2001) Q. J. Nucl. Med., 45, 189200.[ISI][Medline]
Bodnar,R.J. and Hadjimarkou,M.M. (2002) Peptides, 23, 23072365.[CrossRef][ISI][Medline]
Buchberger,A. (2002) Trends Cell Biol., 12, 216221.[CrossRef][ISI][Medline]
Burnett,B. Li,F. and Pittman,R.N. (2003) Hum. Mol. Genet., 12, 31953205.
Celis,E. (2002) J. Clin. Invest., 110, 17651768.
Delaglio,F., Grzesiek,S., Vuister,G.W., Zhu,G., Pfeifer,J. and Bax,A. (1995) J. Biomol. NMR, 6, 277293.[ISI][Medline]
Di Fiore,P.P., Polo,S. and Hofmann,K. (2003) Nat. Rev. Mol. Cell. Biol., 4, 491497.[CrossRef][ISI][Medline]
Fernandez,C., Hilty,C., Bonjour,S., Adeishvili,K., Pervushin,K. and Wuthrich,K. (2001) FEBS Lett., 504, 173178.[CrossRef][ISI][Medline]
Fishbein,V.A., Coy,D.H., Hocart,S.J., Jiang,N.Y., Mrozinski,J.E.,Jr, Mantey,S.A. and Jensen,R.T. (1994) Peptides, 15, 95100.[CrossRef][ISI][Medline]
Fisher,R.D., Wang,B., Alam,S.L., Higginson,D.S., Robinson,H., Sundquist,W.I. and Hill,C.P. (2003) J. Biol. Chem., 278, 2897628984.
Fujiwara,K., Tenno,T., Sugasawa,K., Jee,J.G., Ohki,I., Kojima,C., Tochio,H., Hiroaki,H., Hanaoka,F., Shirakawa,M. (2004) J. Biol. Chem., 279, 47604767.
Giragossian,C., Pellegrini,M., Mierke,D.F., (2002) Can. J. Physiol. Pharm., 80, 383387.[CrossRef][ISI][Medline]
Goda,K., Tenno,T., Takasu,H., Hiroaki,H., Shirakawa,M. (2004) Protein Sci., 13, 652658.
Gozes,I. and Furman,S. (2003) Curr. Pharm Des., 9, 483494.[ISI][Medline]
Haghjoo,K., Cash,P.W., Farid,R.S., Komisaruk,B.R., Jordan,F. and Pochapsky,S.S. (1996) Pept. Res., 9, 327331.[ISI][Medline]
Hofmann,K. and Falquet,L. (2001) Trends Biochem. Sci., 26, 347350.[CrossRef][ISI][Medline]
Ichinose,M., Sawada,M. and Maeno,T. (1994) Regul. Pept., 54, 457466.[CrossRef][ISI][Medline]
Inooka,H., Ohtaki,T., Kitahara,O., Ikegami,T., Endo,S., Kitada,C., Ogi,K., Onda,H., Fujino,M. and Shirakawa,M. (2001) Nat. Struct. Biol., 8, 161165.[CrossRef][ISI][Medline]
Jacobsen,J.S. (2002) Curr. Top. Med. Chem., 2, 343352.[Medline]
Jones,D.H., Ball,E.H., Sharpe,S., Barber,K.R. and Grant,C.W. (2000) Biochemistry, 39, 18701878.[CrossRef][ISI][Medline]
Kami,K., Takeya,R., Sumimoto,H. and Kohda,D. (2002) EMBO J., 21, 42684276.
Kay,L.E., Keifer,P. and Saarinen,T. (1992) J. Am. Chem. Soc., 114, 1066310665.[ISI]
Laburthe,M. and Couvineau,A. (2002) Regul. Pept., 108, 165173.[CrossRef][ISI][Medline]
Laburthe,M., Couvineau,A. and Marie,J.C. (2002) Receptors Channels, 8, 137153.[ISI][Medline]
Lauta,V.M. (2000) Fundam. Clin. Pharmacol., 14, 425442.[ISI][Medline]
LaVallie,E.R., DiBlasio,E.A., Kovacic,S., Grant,K.L., Schendel,P.F. and McCoy,J.M. (1993) Biotechnology (NY), 11, 187193.[ISI][Medline]
Lindhout,D.A., Thiessen,A., Schieve D. and Sykes,B.D. (2003) Protein Sci., 12, 17861791.
Majerle,A., Kidric,J. and Jerala,R. (2000) J. Biomol NMR., 18, 145151.[CrossRef][ISI][Medline]
Miroux,B. and Walker,J.E. (1996) J. Mol. Biol., 260, 289298.[CrossRef][ISI][Medline]
Mueller,T.D. and Feigon,J. (2003) EMBO J., 22, 46344645.
Nathisuwan,S. and Talbert,R.L. (2002) Pharmacotherapy, 22, 2742.[ISI][Medline]
Neri,D., Szyperski,T., Otting,G., Senn,H. and Wuthrich,K. (1989) Biochemistry, 28, 75107516.[ISI][Medline]
Pachter,J.A., Marshak,D.W., Lam,D.M. and Fry,K.R. (1989) Neuroscience, 31, 507519.[CrossRef][ISI][Medline]
Pervushin,K. (2000) Q. Rev. Biophys., 33, 161197.[CrossRef][ISI][Medline]
Prigge,S.T., Mains,R.E., Eipper,B.A. and Amzel,L.M. (2000) Cell. Mol. Life Sci., 57, 12361259.[ISI][Medline]
Rubinstein,I., Dagar,S., Sethi,V., Krishnadas,A. and Onyuksel,H. (2001) Peptides, 22, 671675.[CrossRef][ISI][Medline]
Sharon,M., Gorlach,M., Levy,R., Hayek,Y. and Anglister,J. (2002) Protein Expr. Purif., 24, 374383.[CrossRef][ISI][Medline]
Sherwood,N.M., Krueckl,S.L. and McRory,J.E. (2000) Endocr. Rev., 21, 619670.
Smith,D.B. and Johnson,K.S. (1988) Gene, 67, 3140.[CrossRef][ISI][Medline]
Studier,F.W. and Moffatt,B.A. (1986) J. Mol. Biol., 189, 113130.[ISI][Medline]
Swanson,K.A., Kang,R.S., Stamennova,S.D., Hick,L. and Radhakrishnan,I. (2003) EMBO J., 45974606.
Takahashi,H., Nakanishi,T., Kami,K., Arata,Y. and Shimada,I. (2000) Nat. Struct. Biol., 7, 220223.[CrossRef][ISI][Medline]
Uegaki,K., Nemoto,N., Shimizu,M., Wada,T., Kyogoku,Y. and Kobayashi,Y. (1996) FEBS Lett., 379, 4750.[CrossRef][ISI][Medline]
Vaudry,D., Gonzalez,B.J., Basille,M., Yon,L., Fournier,A. and Vaudry,H. (2000) Pharmacol. Rev., 52, 269324.
Received December 17, 2003; revised March 31, 2004; accepted May 6, 2004.
Edited by Roger Williams
|